Physician profile
Robert M Mccarron
NPI 1831173087
$135,884.40
in general payments reported to CMS, 2019-2025
5 companies · $75K in 2025
The $75K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,511 · 2022: $8,841 · 2023: $23K · 2024: $27K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Consulting Fee: $38K · Travel and Lodging: $10K · Food and Beverage: $2,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,190.50 |
| Consulting Fee | $38,245.75 |
| Travel and Lodging | $10,103.62 |
| Food and Beverage | $2,992.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48,743.40 | 2025 | Caplyta |
| Alkermes, INC. | $48,164.77 | 2023-2025 | Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31,754.93 | 2021-2025 | Rejoyn, Abilify Mycite, Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $7,155.00 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $66.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mccarron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.